Nuclear receptor coregulators: Modulators of pathology and therapeutic targets

Nature Reviews Endocrinology

Volumn 8, Issue 10, 2012, Pages 598-604

  Lonard, David M ^a   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; ANTIESTROGEN; BRAIN NATRIURETIC PEPTIDE; CALVASCULIN; CARNITINE; CELL NUCLEUS RECEPTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE; GLUCOSE 6 PHOSPHATASE; HISTONE DEACETYLASE 4; HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPIN 2 PROTEIN; MYOCARDIN; MYOCARDIN RELATED TRANSCRIPTION FACTOR A; NUCLEAR RECEPTOR COACTIVATOR 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; RECEPTOR INTERACTING PROTEIN 140; RETINOID; STEROID; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; THYROID HORMONE; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CARNITINE DEFICIENCY; CELL STRESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIET; DISEASE ASSOCIATION; DRUG TARGETING; ENERGY METABOLISM; ENVIRONMENT; GENE EXPRESSION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOMICS; GLYCOGEN STORAGE DISEASE TYPE 1; HEREDITY; HUMAN; HUNTINGTON CHOREA; MAJEED SYNDROME; METABOLIC DISORDER; METABOLIC REGULATION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEOMICS; REPRODUCTION; REVIEW; RUBENSTEIN TAYBI SYNDROME; SIGNAL TRANSDUCTION; STRESS; THYROID DYSGENESIS; TRANSCRIPTOMICS;

ANIMALS; GENOMICS; HUMANS; PROTEOMICS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 84866607246     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.100     Document Type: Review

References (85)

1. Lonard, D. M., Kumar, R. & O'Malley, B. W. Minireview: the SRC family of coactivators: an entrée to understanding a subset of polygenic diseases? Mol. Endocrinol. 24, 279-285 (2010).
2. Tsai, M. J. & O'Malley, B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63, 451-486 (1994). (Pubitemid 24218640)
3. Lonard, D. M., Lanz, R. B. & O'Malley, B. W. Nuclear receptor coregulators and human disease. Endocr. Rev. 28, 575-587 (2007). (Pubitemid 47236337)
4. Lonard, D. M. & O'Malley, B. W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol. Cell 27, 691-700 (2007). (Pubitemid 47333229)
5. Xu, J. & Li, Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol. Endocrinol. 17, 1681-1692 (2003). (Pubitemid 37072287)
6. Chopra, A. R. et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science 322, 1395-1399 (2008). (Pubitemid 352775254)
7. Chopra, A. R. et al. Cellular energy depletion resets whole-body energy by promoting coactivator-mediated dietary fuel absorption. Cell Metab. 13, 35-43 (2011).
8. Picard, F. et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111, 931-941 (2002). (Pubitemid 36044686)
9. Louet, J. F. et al. Oncogenic steroid receptor coactivator-3 is a key regulator of the white adipogenic program. Proc. Natl Acad. Sci. USA 103, 17868-17873 (2006).
10. York, B. et al. Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy. Cell Metab. 15, 752-763 (2012).
11. Wu, Z. & Boss, O. Targeting PGC-1α to control energy homeostasis. Expert Opin. Ther. Targets 11, 1329-1338 (2007). (Pubitemid 47604072)
12. Handschin, C. The biology of PGC-1α and its therapeutic potential. Trends Pharmacol. Sci. 30, 322-329 (2009).
13. Andersen, G. et al. PGC-1α Gly482Ser polymorphism associates with hypertension among Danish whites. Hypertension 45, 565-570 (2005). (Pubitemid 40411260)
14. Ek, J. et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 44, 2220-2226 (2001). (Pubitemid 34015475)
15. Sonoda, J., Mehl, I. R., Chong, L. W., Nofsinger, R. R. & Evans, R. M. PGC-1β controls mitochondrial metabolism to modulate circadian activity, adaptive thermogenesis, and hepatic steatosis. Proc. Natl Acad. Sci. USA 104, 5223-5228 (2007). (Pubitemid 47186203)
16. Lelliott, C. J. et al. Ablation of PGC-1β results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS Biol. 4, e369 (2006).
17. Uldry, M. et al. Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab. 3, 333-341 (2006).
18. Scarpulla, R. C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev. 88, 611-638 (2008). (Pubitemid 351520089)
19. Quintanilla, R. A., Jin, Y. N., Fuenzalida, K., Bronfman, M. & Johnson, G. V. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J. Biol. Chem. 283, 25628-25637 (2008).
20. Eloranta, J. J. & Kullak-Ublick, G. A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 433, 397-412 (2005). (Pubitemid 39592794)
21. Petrij, F. et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376, 348-351 (1995).
22. Roelfsema, J. H. et al. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am. J. Hum. Genet. 76, 572-580 (2005). (Pubitemid 40432165)
23. Kazantsev, A. G. & Thompson, L. M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7, 854-868 (2008).
24. Roelfsema, J. H. & Peters, D. J. Rubinstein-Taybi syndrome: clinical and molecular overview. Expert Rev. Mol. Med. 9, 1-16 (2007). (Pubitemid 47616466)
25. Nishihara, E. et al. SRC-1 null mice exhibit moderate motor dysfunction and delayed development of cerebellar Purkinje cells. J. Neurosci. 23, 213-222 (2003). (Pubitemid 36050421)
26. Charlier, T. D. Importance of steroid receptor coactivators in the modulation of steroid action on brain and behavior. Psychoneuroendocrinology 34 (Suppl. 1), S20-S29 (2009).
27. Reddy, S. D. et al. Multiple coregulatory control of tyrosine hydroxylase gene transcription. Proc. Natl Acad. Sci. USA 108, 4200-4205 (2011).
28. Di Palma, T. et al. TAZ is a coactivator for Pax8 and TTF-1, two transcription factors involved in thyroid differentiation. Exp. Cell Res. 315, 162-175 (2009).
29. de Cristofaro, T. et al. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur. J. Cancer 47, 926-933 (2011).
30. Choi, H. K. et al. The functional role of the CARM1-SNF5 complex and its associated HMT activity in transcriptional activation by thyroid hormone receptor. Exp. Mol. Med. 39, 544-555 (2007).
31. Donkor, J. et al. A conserved serine residue is required for the phosphatidate phosphatase activity but not the transcriptional coactivator functions of lipin-1 and lipin-2. J. Biol. Chem. 284, 29968-29978 (2009).
32. Finck, B. N. et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway. Cell Metab. 4, 199-210 (2006). (Pubitemid 44283957)
33. Cen, B. et al. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes. Mol. Cell. Biol. 23, 6597-6608 (2003). (Pubitemid 37075770)
34. Kuwahara, K. et al. Myocardin-related transcription factor A is a common mediator of mechanical stress- and neurohumoral stimulation-induced cardiac hypertrophic signaling leading to activation of brain natriuretic peptide gene expression. Mol. Cell. Biol. 30, 4134-4148 (2010).
35. Chen, J. D. & Evans, R. M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377, 454-457 (1995).
36. Hörlein, A. J. et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377, 397-404 (1995).
37. Perissi, V., Jepsen, K., Glass, C. K. & Rosenfeld, M. G. Deconstructing repression: evolving models of corepressor action. Nat. Rev. Genet. 11, 109-123 (2010).
38. Hsia, E. Y., Goodson, M. L., Zou, J. X., Privalsky, M. L. & Chen, H. W. Nuclear receptor coregulators as a new paradigm for therapeutic targeting. Adv. Drug Deliv. Rev. 62, 1227-1237 (2010).
39. Yoh, S. M., Chatterjee, V. K. & Privalsky, M. L. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol. Endocrinol. 11, 470-480 (1997). (Pubitemid 27147015)
40. Quintás-Cardama, A., Santos, F. P. & Garcia-Manero, G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25, 226-235 (2011).
41. Ng, D. et al. Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR. Nat. Genet. 36, 411-416 (2004). (Pubitemid 38437266)
42. Yamamoto, Y. et al. BCOR as a novel fusion partner of retinoic acid receptor α in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood 116, 4274-4283 (2010).
43. White, R. et al. Role of RIP140 in metabolic tissues: connections to disease. FEBS Lett. 582, 39-45 (2008). (Pubitemid 350297242)
44. Williams, S. R. et al. Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. Am. J. Hum. Genet. 87, 219-228 (2010).
45. Vega, R. B. et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119, 555-566 (2004). (Pubitemid 39482354)
46. Ito, K. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352, 1967-1976 (2005). (Pubitemid 40638367)
47. Ito, K. et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl Acad. Sci. USA 99, 8921-8926 (2002). (Pubitemid 34693659)
48. Hew, M. et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am. J. Respir. Crit. Care Med. 174, 134-141 (2006). (Pubitemid 44015386)
49. Adcock, I. M., Ito, K. & Barnes, P. J. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2, 445-455 (2005). (Pubitemid 43879443)
50. Wang, S. et al. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc. Natl Acad. Sci. USA 106, 151-156 (2009).
51. Flågeng, M. H. et al. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br. J. Cancer 101, 1253-1260 (2009).
52. Fluck, M. M. & Schaffhausen, B. S. Lessons in signalling and tumourigenesis from polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 73, 542-563 (2009).
53. Wang, H. et al. Overexpression and gender-specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study. J. Histochem. Cytochem. 58, 1121-1127 (2010).
54. Cai, D. et al. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 70, 6477-6485 (2010).
55. John, T., Liu, G. & Tsao, M. S. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28 (Suppl. 1), S14-S23 (2009).
56. Adjei, A. A. K-ras as a target for lung cancer therapy. J. Thorac. Oncol. 3 (Suppl. 2), S160-S163 (2008). (Pubitemid 351786750)
57. Yamamoto, H. et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68, 6913-6921 (2008).
58. Schmid, K. et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin. Cancer Res. 15, 4554-4560 (2009).
59. Ye, Y., Wang, D., Su, C., Rong, T. & Guo, A. Combined detection of p53, p16, Rb, and EGFR mutations in lung cancer by suspension microarray. Genet. Mol. Res. 8, 1509-1518 (2009).
60. Sanford, M. & Scott, L. J. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small-cell lung cancer. Drugs 69, 2303-2328 (2009).
61. Carlson, J. J. Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. Expert Rev. Pharmacoecon. Outcomes Res. 9, 409-416 (2009).
62. Zhou, H. J. et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 65, 7976-7983 (2005).
63. Wu, R. C. et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by IκB kinase. Mol. Cell. Biol. 22, 3549-3561 (2002).
64. Yi, P. et al. Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol. Cell 29, 465-476 (2008). (Pubitemid 351291678)
65. Louie, M. C., Zou, J. X., Rabinovich, A. & Chen, H. W. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol. Cell. Biol. 24, 5157-5171 (2004). (Pubitemid 38738153)
66. Chen, T. Nuclear receptor drug discovery. Curr. Opin. Chem. Biol. 12, 418-426 (2008).
67. Wells, J. A. & McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007). (Pubitemid 350273630)
68. Goldsmith, K. C. & Hogarty, M. D. Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer. Curr. Opin. Investig. Drugs 10, 559-571 (2009).
69. Shangary, S. & Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49, 223-241 (2009).
70. Esposito, E. & Cuzzocrea, S. TNF-α as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr. Med. Chem. 16, 3152-3167 (2009).
71. Marchioni, F. & Zheng, Y. Targeting rho GTPases by peptidic structures. Curr. Pharm. Des. 15, 2481-2487 (2009).
72. Kadow, J., Wang, H. G. & Lin, P. F. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr. Opin. Investig. Drugs 7, 721-726 (2006). (Pubitemid 44263176)
73. Rodriguez, A. L., Tamrazi, A., Collins, M. L. & Katzenellenbogen, J. A. Design, synthesis, and in vitro biological evaluation of small-molecule inhibitors of estrogen receptor α coactivator binding. J. Med. Chem. 47, 600-611 (2004). (Pubitemid 38129718)
74. Williams, A. B., Weiser, P. T., Hanson, R. N., Gunther, J. R. & Katzenellenbogen, J. A. Synthesis of biphenyl proteomimetics as estrogen receptor α coactivator binding inhibitors. Org. Lett. 11, 5370-5373 (2009).
75. Mettu, N. B. et al. The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. Mol. Endocrinol. 21, 2361-2377 (2007). (Pubitemid 47529351)
76. Wang, Y. et al. Small-molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol. Endocrinol. 25, 2041-2053 (2011).
77. Xu, J. et al. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl Acad. Sci. USA 97, 6379-6384 (2000). (Pubitemid 30412722)
78. Xu, J. et al. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279, 1922-1925 (1998). (Pubitemid 28168645)
79. Malovannaya, A. et al. Analysis of the human endogenous coregulator complexome. Cell 145, 787-799 (2011).
80. Han, S. J., Lonard, D. M. & O'Malley, B. W. Multi-modulation of nuclear receptor coactivators through post-translational modifications. Trends Endocrinol. Metab. 20, 8-15 (2009).
81. Frazer, K. A., Murray, S. S., Schork, N. J. & Topol, E. J. Human genetic variation and its contribution to complex traits. Nat. Rev. Genet. 10, 241-251 (2009).
82. Cooper, J. D. et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat. Genet. 40, 1399-1401 (2008).
83. Yang, J. J. et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301, 393-403 (2009).
84. Hartmaier, R. J. et al. Nuclear receptor coregulator SNP discovery and impact on breast cancer risk. BMC Cancer 9, 438 (2009).
85. Voight, B. F., Kudaravalli, S., Wen, X. & Pritchard, J. K. A map of recent positive selection in the human genome. PLoS Biol. 4, e72 (2006).